Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BREVICON 28-DAY vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive; ethinyl estradiol and norethindrone suppress gonadotropin secretion (FSH and LH) via negative feedback, inhibiting ovulation. Additionally, alters cervical mucus consistency and endometrial lining to impede sperm penetration and implantation.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy,Acne vulgaris (off-label in some guidelines),Menstrual cycle irregularities (off-label)
Prevention of pregnancy (FDA-approved)
One tablet (0.5 mg norethindrone and 35 mcg ethinyl estradiol) orally once daily for 28 days (21 active tablets followed by 7 inert tablets).
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Norethindrone: 8-11 hours; Ethinyl estradiol: 13-27 hours; half-life for ethinyl estradiol allows once-daily dosing
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Hepatic; ethinyl estradiol metabolized primarily via CYP3A4; norethindrone metabolized via reduction and conjugation (sulfation and glucuronidation).
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Renal: ~40% as metabolites and unchanged drug; fecal/biliary: ~60% as metabolites
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
Norethindrone: ~61% bound to albumin and SHBG; Ethinyl estradiol: ~97% bound to albumin
~99% bound to serum albumin and sex hormone-binding globulin.
Norethindrone: 4 L/kg; Ethinyl estradiol: 2-4 L/kg; indicates extensive tissue distribution
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral: ~64% for norethindrone; ~40% for ethinyl estradiol due to first-pass metabolism
Oral: ~70% due to first-pass metabolism.
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (GFR <30 m L/min) or dialysis, use is not recommended due to potential fluid retention and hypertension.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in acute hepatic disease, cholestatic jaundice of pregnancy or prior oral contraceptive use, or severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), use is not recommended unless benefits outweigh risks; close monitoring of hepatic function advised.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Safety and efficacy in postmenarchal adolescents are established. Dosing is the same as adults: one tablet orally once daily for 28 days. Use before menarche is not indicated.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for use in postmenopausal women. No specific dosing adjustments are provided for elderly patients as the drug is not intended for this population.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases risk of serious cardiovascular events from oral contraceptive use. Risk increases with age (especially in women over 35 years) and with number of cigarettes smoked. Women who use oral contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Increased risk of thromboembolic events (especially in smokers, obese, or hypertension), myocardial infarction, stroke, hepatic neoplasia, gallbladder disease, hypertension, and carbohydrate/lipid metabolism effects. Should be discontinued if jaundice, visual disturbances, or migraine occur. May decrease bone density in long-term use.
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Known or suspected pregnancy; history of thrombophlebitis, thromboembolic disorders, or cerebrovascular disease; current or history of breast cancer or estrogen-dependent neoplasia; undiagnosed abnormal genital bleeding; hepatic adenoma or carcinoma; known or suspected hypersensitivity to components; use with Hepatitis C combination therapy containing ombitasvir/paritaprevir/ritonavir with or without dasabuvir.
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
Grapefruit juice may increase ethinyl estradiol levels; avoid excessive consumption. No other significant food interactions.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
Pregnancy category X. Estrogen/progestin combination contraceptives are contraindicated in pregnancy due to risk of fetal harm, including cardiovascular and limb defects, particularly in the first trimester. Use in second and third trimesters is associated with increased risk of fetal genital tract abnormalities and other adverse outcomes.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Excreted in breast milk in small amounts; may reduce milk production and affect infant. M/P ratio not established for Brevicon. Use is not recommended during breastfeeding due to potential for adverse effects on the infant and lactation.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
Contraindicated in pregnancy; no dose adjustment recommended. Discontinue immediately if pregnancy is suspected or confirmed. No pharmacokinetic changes require dose adjustments because use during pregnancy is prohibited.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
Breakthrough bleeding is common in first 3 cycles; counsel patients to continue dosing. Efficacy may be reduced with strong CYP3A4 inducers (e.g., rifampin, carbamazepine, St. John's wort). If vomiting occurs within 3-4 hours of dose, use backup contraception. Consistent timing of daily dose reduces pregnancy risk.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one tablet daily at the same time, even if you don't have sex that day.,Use back-up contraception (e.g., condoms) if you miss a pill or start late.,Breakthrough spotting may occur, especially in the first few months; do not stop taking your pills.,Smoking increases risk of serious cardiovascular side effects, especially if over 35 years old.,Check pill package for inactive (placebo) pills in the last week.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BREVICON 28-DAY vs AFIRMELLE, answered by our medical review team.
BREVICON 28-DAY is a Oral Contraceptive that works by Combination oral contraceptive; ethinyl estradiol and norethindrone suppress gonadotropin secretion (FSH and LH) via negative feedback, inhibiting ovulation. Additionally, alters cervical mucus consistency and endometrial lining to impede sperm penetration and implantation.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BREVICON 28-DAY and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BREVICON 28-DAY is: One tablet (0.5 mg norethindrone and 35 mcg ethinyl estradiol) orally once daily for 28 days (21 active tablets followed by 7 inert tablets).. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BREVICON 28-DAY and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BREVICON 28-DAY is classified as Category C. Pregnancy category X. Estrogen/progestin combination contraceptives are contraindicated in pregnancy due to risk of fetal harm, including cardiovascular and limb defects, particula. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.